CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Mouse Allergenic Extractbiological
Likely dose
Mouse Allergenic Extract 0.4 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02532179
NCT02532179Phase 2Completed
CompareCT.gov

A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 25, 2015·Updated Mar 7, 2018

In Brief

A Phase 2 clinical trial evaluating Mouse Allergenic Extract for Asthma and Perennial Allergic Rhinitis. Completed, enrolled 12 participants across 4 sites.

Detailed Summary

This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity. The study is designed to evaluate: * the safety of this therapy when given by injection * biomarkers of the immune response and * whether the therapy would be effective in treating allergic asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Perennial Allergic Rhinitis
CountriesUnited States
CollaboratorsInner-City Asthma Consortium

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 25, 2015
Enrollment StartOct 1, 2015
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.9 years ago

Interventions

Mouse Allergenic Extractbiological

Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.